Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Monday.

Separately, HC Wainwright reiterated a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP remained flat at $2.38 during midday trading on Monday. The stock had a trading volume of 66,159 shares, compared to its average volume of 136,130. The business's fifty day moving average is $2.39 and its 200 day moving average is $2.41. The stock has a market cap of $96.70 million, a price-to-earnings ratio of 9.15 and a beta of 1.77. Oramed Pharmaceuticals has a fifty-two week low of $1.67 and a fifty-two week high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.21. As a group, equities research analysts predict that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Murchinson Ltd. lifted its position in Oramed Pharmaceuticals by 23.2% in the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock worth $4,369,000 after purchasing an additional 320,495 shares during the period. Renaissance Technologies LLC boosted its position in shares of Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock worth $81,000 after purchasing an additional 10,774 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth approximately $68,000. Finally, XTX Topco Ltd acquired a new stake in Oramed Pharmaceuticals during the second quarter valued at approximately $40,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.